Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TmPSMA-02 CAR T Cells in Metastatic Castrate-Resistant Prostate Cancer
NCT06046040Phase 1Active, not recruiting
- Sponsor
- University of Pennsylvania
- Start
- Jan 2024
- Primary completion
- Jan 2027
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label trial of TmPSMA-02 in metastatic castration-resistant prostate cancer (mCRPC) (4 arms), sponsored by University of Pennsylvania. Primary endpoints: Dose Limiting Toxicities at 28 days, Maximum Tolerated Dose at 28 days and 1 more. Started Jan 2024; status: active, not recruiting.
02
Drugs
TmPSMA-02
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT06046040.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06046040.